Reviva Pharmaceuticals Plans $50M Offering Amid Trials

Introduction

Reviva Pharmaceuticals Holdings Inc. (NASDAQ: RVPH) is a clinical-stage pharmaceutical company based in Santa Clara, California. The firm focuses on discovering and developing therapies for central nervous system, respiratory, and metabolic diseases characterized by unmet medical needs. Its chemical genomics-driven platform facilitates the in-house discovery of new chemical entities, with brilaroxazine (RP5063) as its lead candidate currently in clinical development for indications including schizophrenia, bipolar disorder, major depressive disorder, Alzheimer’s and Parkinson’s disease psychosis, and attention deficit hyperactivity disorder (ADHD).

Corporate structure

Reviva employs between 11 and 50 professionals, including drug developers, clinical operations specialists, and regulatory affairs experts. Founder, President, and CEO Laxminarayan Bhat, Ph.D., has experience in advancing drug candidates through clinical trials and securing meetings with the U.S. Food and Drug Administration (FDA). As a Nasdaq Capital Market-listed company trading under the ticker RVPH, Reviva maintains a patent portfolio alongside its proprietary chemistry and genomics technologies.

Recent developments and news

On May 30, 2025, Reviva entered into an at-market issuance sales agreement with B. Riley Securities and Alliance Global Partners to offer up to $50 million of its common stock. A preliminary prospectus supplement was filed on June 25, 2025, noting the inclusion of Series C and D warrants alongside common shares. No minimum offering amount is required for closing.

At the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference, a pre-recorded corporate update from Dr. Bhat became available on June 16, covering the company’s strategic plans and pipeline progress. On June 2, 2025, Reviva reported results from the one-year open-label extension of its Phase 3 RECOVER study in schizophrenia, highlighting sustained efficacy across symptom domains along with favorable safety and tolerability results. A virtual investor webcast on the same date reviewed these findings.

Financial and strategic analysis

As of the market close on June 26, 2025, RVPH shares traded at $0.4407, reflecting a decline of 42.29% over the prior measurement period, with a trading volume of 388,953 shares. The company's intraday market capitalization is approximately $32 million. Financials for the trailing twelve months indicate a net loss of $28.9 million, a diluted EPS of –$0.78, and levered free cash flow of –$18.5 million. Reviva holds $5.3 million in cash and has no long-term debt. The at-market offering is intended to strengthen the company’s financial position and support global Phase 3 trials for brilaroxazine, as well as advance RP1208, a triple reuptake inhibitor in earlier development.

Market position and industry context

Reviva operates in the competitive CNS therapeutic sector, where safety, tolerability, and differentiated efficacy are essential for regulatory approval and commercial success. The company’s discovery platform and internally developed pipeline position it to target high-need disorders such as schizophrenia and bipolar disorder. However, the lack of product revenue and reliance on external funding may contribute to stock volatility. Key upcoming events include the initiation of Phase 3 trials, enrollment milestones, and data releases that could influence investor sentiment and market valuation.

tl;dr

On June 25, 2025, Reviva filed a prospectus supplement to raise up to $50 million through an at-market offering. A June 2 virtual investor webcast discussed positive results from its Phase 3 schizophrenia study of brilaroxazine. The company is preparing for global Phase 3 trials following an FDA End-of-Phase 2 meeting and issued a corporate update on June 16. Upcoming catalysts include trial enrollment milestones and data releases from its Phase 3 programs.